These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32927121)

  • 1. Real-World Evaluation of Factors for Interstitial Lung Disease Incidence and Radiologic Characteristics in Patients With EGFR T790M-positive NSCLC Treated With Osimertinib in Japan.
    Gemma A; Kusumoto M; Sakai F; Endo M; Kato T; Saito Y; Baba T; Sata M; Yamaguchi O; Yabuki Y; Nogi Y; Jinushi M; Sakamoto K; Sugeno M; Tamura R; Tokimoto T; Ohe Y
    J Thorac Oncol; 2020 Dec; 15(12):1893-1906. PubMed ID: 32927121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of afatinib for the treatment of non-small-cell lung cancer following osimertinib-induced interstitial lung disease: A retrospective study.
    Nasu S; Suzuki H; Shiroyama T; Tanaka A; Samejima Y; Kanai T; Noda Y; Morishita N; Okamoto N; Hirashima T
    Invest New Drugs; 2020 Dec; 38(6):1915-1920. PubMed ID: 32542461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma.
    Kodama H; Wakuda K; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kawamura T; Kobayashi H; Omori S; Ono A; Kenmotsu H; Naito T; Murakami H; Endo M; Takahashi T
    Invest New Drugs; 2021 Apr; 39(2):571-577. PubMed ID: 32955628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of osimertinib in a Japanese compassionate use program.
    Fujiwara Y; Goto Y; Kanda S; Horinouchi H; Yamamoto N; Sakiyama N; Ando Makihara R; Ohe Y
    Jpn J Clin Oncol; 2017 Jul; 47(7):625-629. PubMed ID: 28419328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world data on treatment outcomes in
    Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
    Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Osimertinib Re-challenge for EGFR-mutant NSCLC after 
Osimertinib-induced Interstitial Lung Disease: A Case Report].
    Gu J; Bai F; Song L; Wang Y
    Zhongguo Fei Ai Za Zhi; 2021 Nov; 24(11):804-807. PubMed ID: 34802213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer.
    Uchida T; Kaira K; Yamaguchi O; Mouri A; Shiono A; Miura Y; Hashimoto K; Nishihara F; Murayama Y; Kobayashi K; Kagamu H
    Thorac Cancer; 2019 Apr; 10(4):975-979. PubMed ID: 30864291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful Treatment with Afatinib after Osimertinib-induced Interstitial Lung Disease in a Patient with EGFR-mutant Non-small-cell Lung Cancer.
    Nishima S; Miyanaga A; Saito S; Yuasa M; Takahashi S; Kashiwada T; Sugano T; Noro R; Minegishi Y; Terasaki Y; Saito Y; Kubota K; Seike M; Gemma A
    Intern Med; 2021 Feb; 60(4):591-594. PubMed ID: 32999231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: An open-label, randomised phase 2 clinical trial.
    Tanaka K; Asahina H; Kishimoto J; Miyata Y; Uchida T; Watanabe K; Hamai K; Harada T; Tsubata Y; Sugawara S; Kobayashi K; Sugio K; Oizumi S; Okamoto I
    Eur J Cancer; 2021 May; 149():14-22. PubMed ID: 33813328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
    Tsubata Y; Watanabe K; Saito R; Nakamura A; Yoshioka H; Morita M; Honda R; Kanaji N; Ohizumi S; Jingu D; Nakagawa T; Nakazawa K; Mouri A; Takeuchi S; Furuya N; Akazawa Y; Miura K; Ichihara E; Maemondo M; Morita S; Kobayashi K; Isobe T
    Int J Clin Oncol; 2022 Jan; 27(1):112-120. PubMed ID: 34643820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes and safety of osimertinib plus anlotinib for patients with previously treated EGFR T790M-positive NSCLC: A retrospective study.
    Zhou B; Gong Q; Li B; Qie HL; Li W; Jiang HT; Li HF
    J Clin Pharm Ther; 2022 May; 47(5):643-651. PubMed ID: 35023208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.
    Provencio M; Terrasa J; Garrido P; Campelo RG; Aparisi F; Diz P; Aguiar D; García-Giron C; Hidalgo J; Aguado C; González JG; Esteban E; Gómez-Aldavarí L; Moran T; Juan O; Chara LE; Marti JL; Castro RL; Ortega AL; Moreno EM; Coves J; Sánchez Peña AM; Bosch-Barrera J; Gastaldo AS; Núñez NF; Del Barco E; Cobo M; Isla D; Majem M; Navarro F; Calvo V
    BMC Cancer; 2021 Mar; 21(1):230. PubMed ID: 33676426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
    Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
    Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe hepatotoxicity due to osimertinib after nivolumab therapy in patients with non-small cell lung cancer harboring EGFR mutation.
    Yamaguchi O; Kaira K; Kawasaki T; Mouri A; Hashimoto K; Shiono A; Shinomiya S; Miura Y; Nishihara F; Murayama Y; Kobayashi K; Mochida S; Kagamu H
    Thorac Cancer; 2020 Apr; 11(4):1045-1051. PubMed ID: 32068351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan.
    Ohe Y; Kato T; Sakai F; Kusumoto M; Endo M; Saito Y; Baba T; Sata M; Yamaguchi O; Sakamoto K; Sugeno M; Tamura R; Tokimoto T; Shimizu W; Gemma A
    Jpn J Clin Oncol; 2020 Aug; 50(8):909-919. PubMed ID: 32548617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication.
    Lee H; Lee HY; Sun JM; Lee SH; Kim Y; Park SE; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2018 Aug; 13(8):1106-1112. PubMed ID: 29775809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.
    Hizal M; Bilgin B; Paksoy N; Açıkgöz Ö; Sezer A; Gürbüz M; Ak N; Yücel Ş; Ayhan M; Erol C; Demirkıran A; Mandel NM; Shbair A; Gökmen İ; Başoğlu T; Paydaş S; Demiray AG; İriağaç Y; Şakalar T; Zeynelgil E; Tatlı AM; Bahçeci A; Güven DC; Caner B; Can A; Gülmez A; Karakaş Y; Yalçın B; Demirkazık A; Bilici A; Aydıner A; Yumuk PF; Şendur MAN
    J Cancer Res Clin Oncol; 2022 Jun; 148(6):1501-1508. PubMed ID: 34331582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Auliac JB; Pérol M; Planchard D; Monnet I; Wislez M; Doubre H; Guisier F; Pichon E; Greillier L; Mastroianni B; Decroisette C; Schott R; Le Moulec S; Arrondeau J; Cortot AB; Gerinière L; Renault A; Daniel C; Falchero L; Chouaid C
    Lung Cancer; 2019 Jan; 127():96-102. PubMed ID: 30642559
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.